Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK’s Form 6-K announces EU approval of Blenrep (belantamab mafodotin) combinations for adults with relapsed/refractory multiple myeloma. The anti-BCMA ADC may now be given with bortezomib + dexamethasone after ≥1 prior therapy or with pomalidomide + dexamethasone after prior lenalidomide exposure.
Authorisation is driven by Phase III data: DREAMM-7 nearly tripled median PFS to 36.6 m vs 13.4 m for a daratumumab triplet (HR 0.41, p<0.00001) and cut death risk 42 % (HR 0.58). DREAMM-8 showed PFS not yet reached vs 12.7 m for control at 21.8 m follow-up. Ocular adverse events were manageable, leading to ≤9 % discontinuations. This becomes the sixth global approval for Blenrep combos and the first EU label enabling use from first relapse, expanding addressable patients (~50 k new EU cases/yr) ahead of pending US and China reviews. No financial figures were disclosed.
GSK continued its 2025 share-buyback programme. On 23 July 2025 the company repurchased 491,680 ordinary shares (≈0.012% of outstanding) at prices between 1,364.50 p and 1,374.50 p, yielding a volume-weighted average price of 1,369.42 p per share. All shares will be held in treasury.
Since the non-discretionary mandate with Merrill Lynch International commenced on 4 June 2025, 16,185,726 shares have been bought back. Treasury stock now totals 234,320,109 shares, representing 5.74 % of voting rights. The company’s share count (ex-treasury) stands at 4,081,064,171 shares, which is the new denominator for FCA transparency notifications.
The filing contains no earnings or strategic updates; it merely records routine execution of the authorised capital-return plan.
GSK plc filed a Form 6-K detailing activity under its ongoing share buyback. On 22 Jul 2025 the company repurchased 506,734 ordinary shares (nominal value 31⅔ p) via Merrill Lynch International at prices between 1,337.50 p and 1,359.00 p, generating a volume-weighted average price of 1,347.53 p. The stock will be held in treasury.
Since the non-discretionary agreement announced on 4 Jun 2025, GSK has bought back 15,694,046 shares. Post-transaction, treasury holdings rise to 233,828,429 shares (5.73 % of total voting rights), leaving 4,081,555,851 shares outstanding exclusive of treasury. The filing includes granular trade data for transparency and confirms the denominator for Disclosure Guidance & Transparency Rules reporting.
GSK plc disclosed that on 21 July 2025 it repurchased 504,228 ordinary shares (nominal 31¼ p) through Merrill Lynch International under its 4 June 2025 non-discretionary buy-back programme. Transaction prices ranged from 1,337p to 1,357p with a VWAP of 1,344.38p, representing a cash outlay of roughly £6.8 million. Since programme inception, 15,187,312 shares have been bought back.
All shares are held in treasury, increasing the treasury balance to 233,321,695 shares, now 5.72 % of total voting rights. Issued share capital (excluding treasury) stands at 4,082,062,585 shares, which becomes the denominator for FCA DTR calculations. No earnings, guidance or other financial data were included.
On 18 Jul 2025, GSK plc bought back 505,771 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its previously announced non-discretionary buy-back programme.
The shares were purchased between 1,319.0 p and 1,360.5 p, with a volume-weighted average price of 1,344.42 p. Since the programme commenced on 4 Jun 2025, GSK has repurchased 14,683,084 shares.
Following this latest transaction, the company now holds 232,817,467 shares in treasury, representing 5.70 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,082,566,813, which investors should use as the denominator when assessing disclosure thresholds under the FCA’s DTR rules.
The filing contains no new earnings or guidance; it solely updates the market on the progress of GSK’s authorised share-repurchase programme.
On 15 Jul 2025, GSK plc repurchased 487,387 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its on-market buy-back. The shares were bought at 1,401.50-1,493.50 p, giving a volume-weighted average price of 1,423.89 p and an estimated cash cost of £6.9 million.
Since the non-discretionary programme began on 4 Jun 2025, GSK has acquired 13,210,173 shares. The company now holds 231,344,556 shares in treasury, equivalent to 5.66 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,084,039,501, which is the denominator investors should use for disclosure calculations under the FCA’s DTR rules.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
